Pages that link to "Q34504188"
Jump to navigation
Jump to search
The following pages link to Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia (Q34504188):
Displaying 50 items.
- Process of Fragment-Based Lead Discovery-A Perspective from NMR (Q26738768) (← links)
- Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway (Q26746697) (← links)
- The clinical implications of gene mutations in chronic lymphocytic leukaemia (Q26749214) (← links)
- Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor (Q28066316) (← links)
- Mitochondrial apoptosis and BH3 mimetics (Q28069552) (← links)
- The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia (Q28075504) (← links)
- The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia (Q28075683) (← links)
- Second-generation inhibitors of Bruton tyrosine kinase (Q28076118) (← links)
- In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia (Q28554677) (← links)
- Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci (Q29248527) (← links)
- Sequencing of chronic lymphocytic leukemia therapies. (Q30240243) (← links)
- Prognostication of chronic lymphocytic leukemia in the era of new agents (Q30240258) (← links)
- Management of elderly and unfit patients with chronic lymphocytic leukemia (Q30243914) (← links)
- The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia (Q30243968) (← links)
- Richter transformation of CLL. (Q30249283) (← links)
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data (Q31096565) (← links)
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group (Q31097476) (← links)
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study (Q33432228) (← links)
- Loss of PUMA (BBC3) does not prevent thrombocytopenia caused by the loss of BCL-XL (BCL2L1). (Q33432478) (← links)
- Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. (Q33433407) (← links)
- Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints (Q33436535) (← links)
- First-line therapy for young patients with CLL. (Q33437322) (← links)
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study (Q33438428) (← links)
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (Q33438494) (← links)
- Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China (Q33649977) (← links)
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia (Q33702409) (← links)
- Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 (Q33779035) (← links)
- Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. (Q33823065) (← links)
- Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors (Q36280596) (← links)
- Potential mechanisms of resistance to venetoclax and strategies to circumvent it. (Q36392035) (← links)
- Distinctive Expression of Bcl-2 Factors in Regulatory T Cells Determines a Pharmacological Target to Induce Immunological Tolerance (Q36632500) (← links)
- Bcl-2 is a critical mediator of intestinal transformation (Q36675203) (← links)
- Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions (Q36735325) (← links)
- The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. (Q37035832) (← links)
- Chronic lymphocytic leukemia therapy: new targeted therapies on the way (Q37113544) (← links)
- Alectinib, Ceritinib, Elotuzumab, and Venetoclax (Q37167686) (← links)
- A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy (Q37168430) (← links)
- High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells (Q37209768) (← links)
- Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia ex vivo (Q37293167) (← links)
- Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice. (Q37330840) (← links)
- Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells (Q37376388) (← links)
- Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. (Q37429218) (← links)
- Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation (Q37521403) (← links)
- How to unleash mitochondrial apoptotic blockades to kill cancers? (Q37587294) (← links)
- New Pharmacotherapies in Chronic Lymphocytic Leukemia (Q37605306) (← links)
- MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. (Q37633585) (← links)
- Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia (Q37637724) (← links)
- The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies (Q37638782) (← links)
- Development of venetoclax for therapy of lymphoid malignancies. (Q37702281) (← links)
- Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. (Q37710733) (← links)